Inhibrx

ProBioGen, Inhibrx ink license agreement

Tuesday, October 25, 2011

ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms.

[Read More]